Sign up
Pharma Capital

Faron Pharmaceuticals garners some encouragement from phase III data; still searching for answers to key questions

It has discovered that a sub-group of patients with higher levels of certain bio-markers showed a reduced mortality rate and increased ventilator-free days
words clinical trial on a folder
Faron is trying to understand and explain a number of anomalies in the results

Faron Pharmaceuticals Ltd (LON:FARN) has made some important observations while assessing the data from its unsuccessful phase III trial of Traumakine for acute respiratory distress syndrome (ARDS).  

It has discovered that a sub-group of patients with higher levels of certain bio-markers (CD73 serum and MxA activation) showed a reduced mortality rate and increased ventilator-free days.

The results from this smaller cohort of 48 people mirrored those seen in the company's positive phase II study.

CLICK HERE: For the update in full 

But, as chief exeutive Dr Markku Jalkanen pointed out, while the feedback was encouraging it still did not explain many of the other results observed from the pivotal clinical assessment of the treatment.

Faron's team is still trying to understand why Traumakine activity was variable in the INTEREST trial compared to previous studies and why the mortality was so low in the group receiving the dummy placebo drug.

"This analysis will continue and we will keep our shareholders and the market informed with progress in due course," Jalkanen said.


Why Invest In Faron Pharmaceuticals Ltd? Read More Here

Register here to be notified of future FARN Company articles
View full FARN profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.